These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1355792)

  • 1. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
    Peck CC; Barr WH; Benet LZ; Collins J; Desjardins RE; Furst DE; Harter JG; Levy G; Ludden T; Rodman JH
    J Pharm Sci; 1992 Jun; 81(6):605-10. PubMed ID: 1355792
    [No Abstract]   [Full Text] [Related]  

  • 2. First-time-in-human dose selection: allometric thoughts and perspectives.
    Boxenbaum H; DiLea C
    J Clin Pharmacol; 1995 Oct; 35(10):957-66. PubMed ID: 8568013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology and toxicology of novel drug delivery systems. Regulatory issues.
    Weissinger J
    Drug Saf; 1990; 5 Suppl 1():107-13. PubMed ID: 2182053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).
    Chiou WL
    Clin Pharmacokinet; 1989 Oct; 17(4):275-90. PubMed ID: 2686884
    [No Abstract]   [Full Text] [Related]  

  • 5. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
    Peck CC; Barr WH; Benet LZ; Collins J; Desjardins RE; Furst DE; Harter JG; Levy G; Ludden T; Rodman JH
    Pharm Res; 1992 Jun; 9(6):826-33. PubMed ID: 1409369
    [No Abstract]   [Full Text] [Related]  

  • 6. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
    Peck CC; Barr WH; Benet LZ; Collins J; Desjardins RE; Furst DE; Harter JG; Levy G; Ludden T; Rodman JH
    Clin Pharmacol Ther; 1992 Apr; 51(4):465-73. PubMed ID: 1563216
    [No Abstract]   [Full Text] [Related]  

  • 7. Integrated pharmacokinetics and pharmacodynamics in drug development.
    Dingemanse J; Appel-Dingemanse S
    Clin Pharmacokinet; 2007; 46(9):713-37. PubMed ID: 17713971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging strategies for drug discovery and development.
    Gross S; Piwnica-Worms D
    Curr Opin Chem Biol; 2006 Aug; 10(4):334-42. PubMed ID: 16822702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.
    Abdel-Rahman SM; Kauffman RE
    Annu Rev Pharmacol Toxicol; 2004; 44():111-36. PubMed ID: 14744241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography for use in microdosing studies.
    Wagner CC; Müller M; Lappin G; Langer O
    Curr Opin Drug Discov Devel; 2008 Jan; 11(1):104-10. PubMed ID: 18175273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Challenges and Potential Opportunities for the Pharmaceutical Sciences to Make Global Impact: An FIP Perspective.
    Tucker G; DeSilva B; Dressman J; Ito M; Kumamoto T; Mager D; Mahler HC; Maitland-van der Zee AH; Pauletti GM; Sasaki H; Shah V; Tang D; Ward M
    J Pharm Sci; 2016 Sep; 105(9):2489-2497. PubMed ID: 26886325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between pharmacokinetics and toxicokinetics.
    Welling PG
    Toxicol Pathol; 1995; 23(2):143-7. PubMed ID: 7569668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biopharmaceutical studies, a key to better toxicology.
    Zbinden G
    Xenobiotica; 1988 Jan; 18 Suppl 1():9-14. PubMed ID: 3344592
    [No Abstract]   [Full Text] [Related]  

  • 14. The study of intravitreal drug pharmacokinetics: does it matter? and if so, how?
    Stewart MW
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):5-7. PubMed ID: 29221430
    [No Abstract]   [Full Text] [Related]  

  • 15. Less is more: the human microdosing concept.
    Garner RC
    Drug Discov Today; 2005 Apr; 10(7):449-51. PubMed ID: 15809185
    [No Abstract]   [Full Text] [Related]  

  • 16. [Age-related changes in pharmacokinetics and pharmacodynamics].
    Akishita M
    Nihon Rinsho; 2013 Nov; 71(11):1888-91. PubMed ID: 24397155
    [No Abstract]   [Full Text] [Related]  

  • 17. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
    Lappin G; Garner RC
    Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin biopsies for the measurement of clinical pharmacodynamic biomarkers.
    Phillips RL; Sachs AB
    Curr Opin Biotechnol; 2005 Dec; 16(6):687-90. PubMed ID: 16257524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric drug development: formulation considerations.
    Ali AA; Charoo NA; Abdallah DB
    Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).
    Rowland M; Balant L; Peck C
    AAPS PharmSci; 2004 Feb; 6(1):E6. PubMed ID: 15198507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.